A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-05-11
AEs
4
Serious
1
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-07-19 (study day 55); relationship: not assessed
mild
assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-07-23 (study day 59); relationship: not assessed
severe
serious
assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-11 (study day 78); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-01-14 (study day 234); relationship: not assessed
Data queries
No data queries.